Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast

Human Pathology

Volumn 39, Issue 3, 2008, Pages 386-392

  Hanley, Krisztina ^a   Wang, Jianmin ^b   Bourne, Patricia ^a   Yang, Qi ^a   Gao, Allen C ^c   Lyman, Gary ^a   Tang, Ping ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AR; Cytokeratin markers; Ductal carcinoma in situ; Estrogen receptor ; HER 2; Invasive ductal carcinoma; Nuclear grade; Progesterone receptor

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 38749143968     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.07.007     Document Type: Article

References (35)

1. Lillie E., Bernstein L., and Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 5 (2003) 164-173
2. Tamimi R.M., Hankinson S.E., Chen W.Y., Rosner B., and Colditz G.A. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 166 (2006) 1483-1489
3. Moinfar F., Okcu M., Tsybrovsky O., et al. Androgen receptors frequently are expressed in breast carcinomas. Potential relevance to new therapeutic strategies. Cancer 98 (2003) 703-711
4. Riva C., Dainese E., Caprara G., et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 447 (2005) 695-700
5. Berns E.M.J.J., Dirkzwager-Kiel M.J.M., Kuenen-Boumeester V., et al. Androgen pathology dysregulation in BRCA1-mutated breast tumors. Breast Cancer Res Treat 79 (2003) 121-127
6. Liegl B., Horn L.C., and Moinfar F. Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Mod Pathol 18 (2005) 1283-1288
7. Kuenen-Boumeester V., Van der Kwast T.H., Claassen C.C., Hawes S.E., and Lawton J.J. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A (1996) 1560-1565
8. Agoff S.N., Swanson P.E., Linden H., Hawes S.E., and Lawton T.J. Androgen receptor expression in estrogen receptor-negative breast cancer. Am J Clin Pathol 120 (2003) 725-731
9. Schippinger W., Regitnig P., Dandachi N., et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449 (2006) 24-30
10. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H.S., Robertson J.F., and Ellis I.O. Prognostic markers in triple negative breast cancer. Cancer 109 (2007) 25-32
11. Bryan R.M., Mercer R.J., Bennett R.C., Rennie G.C., Lie T.H., and Morgan F.J. Androgen receptors in breast cancer. Cancer 54 (1984) 2436-2440
12. Ingle J.N., Twito D.I., Schaid D.J., et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer, an updated analysis. Cancer 67 (1991) 886-891
13. Boecker W., Moll R., Dervan P., et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atyical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198 (2002) 458-467
14. Tang P., Wang X., Schiffhauer L., et al. Expression patterns of ER-a, PR, Her-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci 36 (2006) 137-143
15. Steinman S., Wang J., Bourne P., Yang Q., and Tang P. Expression of cytokeratin markers, ER-a, PR, Her-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma of the breast. Ann Clin Lab Sci 37 (2007) 127-134
16. Megha T., Ferrari F., Benvenuto A., et al. p53 mutant in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 55 (2002) 461-466
17. Van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratin 17 and 5 identifies a group of breast carcinoma with poor clinical outcome. Am J Pathol 161 (2002) 1991-1996
18. Matos I., Dufloth R., Alvarenga M., et al. p63, cytokeratin 5, and p-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 477 (2005) 688-694
19. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
20. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
21. Holland P., Peterse J.L., Millis R.R., et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11 (1994) 167-180
22. Silverstein M.J., Poller D.N., Waisman J.R., et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345 (1995) 1154-1157
23. Dehm S.M., and Tindall D.J. Regulation of androgen receptor signaling in prostate cancer. Exp Rev Anticancer Ther 5 (2005) 63-74
24. Pienta K.J., and Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12 (2006) 1665-1671
25. Birrell S.N., Hall R.E., and Tilley W.D. Role of the androgen receptor in human breast cancer. J Mammary Cland Biol Neoplasia 3 (1998) 95-103
26. Yu H., Shu X.O., Li B., et al. Joint effect of insulin-like growth factors and sex steroid on breast cancer risk. Cancer Epidemiol Biomark Prev 12 (2003) 1067-1073
27. Somboonporn W., and Davis S.R. Postmenopausal testosterone therapy and breast cancer risk. Maturitas 49 (2004) 267-275
28. Selim A.G.A., El Ayat G., and Wells C.A. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 55 (2002) 14-16
29. Rody A., Diallo R., Poremba C., et al. Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor-alpha and progesterone receptor. Appl Immunohistochem Mol Morphol 13 (2005) 25-29
30. Garreau J.R., Muller P., and Pommier S. Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation. Am J Surg 191 (2006) 576-580
31. Morris K.T., Toth-Fejel S., Schmidt J., Fletcher W.S., and Pommier R.F. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulate breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery 130 (2001) 947-953
32. Suzuki T., Miki Y., Moriya T., et al. 5a-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 120 (2007) 285-291
33. Zagorianakou P., Zagorianakou N., Steanou D., et al. The enigmatic nature of apocrine breast lesions. Virchows Arch 448 (2006) 525-531
34. Leal C., Henrique R., Monteiro P., et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol 32 (2001) 487-493
35. Honma N., Takubo K., Akiyama F., et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 47 (2005) 195-201